Lenalidomide (CC-5013)

Catalog No.S1029

For research use only.

Lenalidomide (CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM in PBMCs. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide promotes cleaved caspase-3 expression and inhibit VEGF expression and induces apoptosis.

Lenalidomide (CC-5013) Chemical Structure

CAS No. 191732-72-6

Selleck's Lenalidomide (CC-5013) has been cited by 138 publications

Purity & Quality Control

Choose Selective E3 ligase Ligand Inhibitors

Biological Activity

Description Lenalidomide (CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM in PBMCs. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide promotes cleaved caspase-3 expression and inhibit VEGF expression and induces apoptosis.
Targets
CRBN [3] VEGF [1] TNF-α [1]
(PBMCs)
13 nM
In vitro

Lenalidomide strongly induces IL-2 and sIL-2R production. Lenalidomide-induced tyrosine phosphorylation of CD28 on T cells is followed by a down-stream activation of NF-κB. [2] Lenalidomide and pomalidomide inhibits autoubiquitination of CRBN in HEK293 T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA). Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplifies pomalidomide-mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression. Long-term selection for Lenalidomide resistance in H929 myeloma cell lines is accompanied by a reduction in CRBN, while in DF15R myeloma cells resistant to both pomalidomide and Lenalidomide, CRBN protein is undetectable. [3] Lenalidomide prevents induction of defects by down-regulating tumor cell inhibitory molecule expression. Lenalidomide prevents induction of tumor-induced T cell lytic synapse dysfunction. Lenalidomide treatment blocks CLL cell-induced T cell actin synapse dysfunction, mimicks antibody blockade, and down-regulates expression of CLL inhibitory ligands and their receptors on T cells. Lenalidomide treatment prevents tumor-induced immune suppression in FL, DLBCL, HL, MM, SCC, and OC and down-regulates immunosuppressive ligand expression on all tumor cells examined. CTL killing function significantly increases following antibody blockade of CLL inhibitory ligands or Lenalidomide treatment compared to control treatments. Treatment of autologous CLL-T cell co-cultures with Lenalidomide reverses impaired CD8+ T cell lytic synapse formation and granzyme B trafficking. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LB771-HNC NUXNfnU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4G3WGlEPTB;Mj6xOVA{QCEQvF2= NGW4Ong9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
L-363 Mny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYX4[5dTUUN3ME2yMlkzOjF{IN88US=> Mk\6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
JAR M1nWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:2b3dWUUN3ME2yMlk4ODBzIN88US=> NWrYdYhyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
EoL-1-cell MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO0c|U6UUN3ME20MlExPTF3IN88US=> MkLzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
BT-549 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzh[pBKSzVyPU[uNlE5PDlizszN NGjuUWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
SK-NEP-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3e1bmlEPTB;Nz64PVUyOiEQvF2= NH[yPZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
BV-173 MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PLU2lEPTB;OD62O|U5PSEQvF2= NWnuUlAxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
HMV-II NVnhR2F4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoT1TWM2OD1zMD6wNVczKM7:TR?= NV[4XIxrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
HCC1806 MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDTPY5HUUN3ME2xNU41PDZ5IN88US=> NIPQT3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
KASUMI-1 M1Lsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M163[2lEPTB;MUGuOVcyKM7:TR?= MnzuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
SK-MEL-28 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTQWo5KSzVyPUGxMlk4PjRizszN MkPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
RPMI-8226 NW\IcJZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfMTWM2OD1zMj62NlQyKM7:TR?= MofWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
T47D MlXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Tt[2lEPTB;MUOuNlA6QSEQvF2= NWntVoZJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
HOP-62 MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33uUmlEPTB;MUOuOFgh|ryP M4j3elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
A2058 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzIb3dKSzVyPUGzMlgyQTlizszN NX:zWpFJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
SW620 M1S5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoWyTWM2OD1zND6yOFc{KM7:TR?= MoXrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
LCLC-103H NYHtbJRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTF2LkS4PVIh|ryP NWPQO2pXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
HAL-01 NGP0VphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTITHNKSzVyPUG0MlU4QTZizszN M3\lUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
PANC-08-13 MmfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjofZd{UUN3ME2xOE46OTB6IN88US=> M33iNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
COLO-684 M3O2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoqzTWM2OD1zNT6zPVc6KM7:TR?= Ml;qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
DEL MkPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTF3LkS5PUDPxE1? Mo[5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
K5 M3vQO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTF4LkG0PFYh|ryP NFHVPIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
SK-MEL-24 M4HmS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vxXGlEPTB;MU[uOFY2OiEQvF2= MknNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
ACN MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\qXGJ{UUN3ME2xOk42Ojl5IN88US=> NWTDOnpFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
H9 NWH2S3JiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorXTWM2OD1zNj62NlYh|ryP Mlj3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
EM-2 NXvPfWZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvWdplKSzVyPUG3MlE1OyEQvF2= MnW4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
HSC-4 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEThe|NKSzVyPUG3MlY3ODFizszN NVnvTJlNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
IGROV-1 M{jiVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXpV41KSzVyPUG3Mlc5OyEQvF2= NFf2XZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
TE-1 NVGxd5ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f5emlEPTB;MUeuPVk3QCEQvF2= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
LN-405 MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ryRmlEPTB;MUmuPVA4PiEQvF2= MknhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
MSTO-211H MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3n0RWlEPTB;MkCuN|U4OyEQvF2= NFLiOlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
MOLT-4 NGjtbmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjOOVJKSzVyPUKwMlU4PTlizszN NWnURnhERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
RS4-11 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLuTWM2OD1{Mj6xOVY{KM7:TR?= MlTkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
ES3 M4nDZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HGbGlEPTB;MkKuOlk3OyEQvF2= NFu0WFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
SBC-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTJ|Lki2PVYh|ryP MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
CTV-1 MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfmTWM2OD1{NT6wNVQ6KM7:TR?= NHjoRpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
HuP-T3 NIPY[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXuTWM2OD1{NT60NFA6KM7:TR?= NGjreZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
HCC2218 NUTKdIdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjO[nF[UUN3ME2yOU42PDB5IN88US=> NFfHPVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
HDLM-2 M1XaV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1OzT2lEPTB;MkiuNlAzPiEQvF2= MnXSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
ABC-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PZU2lEPTB;MkmuOlk4PCEQvF2= MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
MV-4-11 NGjaSHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPOTWM2OD1{OT63N|E4KM7:TR?= MoHrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
WM-115 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmL4TWM2OD1|MD6zNFk6KM7:TR?= NVPqWYVtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
SW1990 M4PVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvBTWM2OD1|MD6zN{DPxE1? NVfZT4R7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
HCC70 NXnCb4xoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\xcXRKSzVyPUOwMlc{PDZizszN NWHKdHJMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
KYSE-520 M2H5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjYdopKSzVyPUOwMlg5OzlizszN NGW0Onc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
JEG-3 MoCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTNzLkG2NVQh|ryP NG\o[Zg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
C8166 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;5W2JKSzVyPUOxMlIzPzRizszN M2K4VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
SK-OV-3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPHTWM2OD1|MT62O|U2KM7:TR?= M{nBT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
NCI-H526 MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDvTWM2OD1|Mj62PFMh|ryP NWHJVoZURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
NKM-1 Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXr5UZZlUUN3ME2zNk46PTZ6IN88US=> MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
ECC10 M1fBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[0TmFlUUN3ME2zOE44PDR|IN88US=> NXfSTXoyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
A2780 M4XPVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXzcmJKSzVyPUO1MlM3ODFizszN NFfxZ3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
KY821 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XKWWlEPTB;M{WuO|Y5OSEQvF2= M13K[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
MKN1 M4S5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXiTWM2OD1|Nj6yNVM4KM7:TR?= NHu2V5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
EKVX NGDrbnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlW4TWM2OD1|Nz60NlEzKM7:TR?= NWj6b2Y6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
EW-16 MlPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTN6LkO4PFUh|ryP MkX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
CTB-1 NEj4O29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vrZ2lEPTB;M{muO|c5QSEQvF2= Ml3OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
COR-L105 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTRyLkS3OFYh|ryP MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
NCI-SNU-5 NGTMcGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTRzLkKwOlkh|ryP NGLiemQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
Mewo MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPkWYx6UUN3ME20NU46QDdzIN88US=> M2XGV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
BCPAP NVvEfYhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnX2TWM2OD12Mz63PVE4KM7:TR?= NUHIV2Q5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
KARPAS-45 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjXTWM2OD12ND6yO|c3KM7:TR?= MkHNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
NCI-H1693 NEjQco1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHWTWM2OD12Nj62PVg3KM7:TR?= M1G3VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
H-EMC-SS M3q5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfzZmFiUUN3ME20PE4{OjJ2IN88US=> MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
697 Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13aUGlEPTB;NUCuN|U1PSEQvF2= Mmm5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
KP-N-YS NUjlclBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoL6TWM2OD13Mj6zNVQzKM7:TR?= NFjrVW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
NCI-H1304 NEjoV3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnyeXZKSzVyPUWyMlcxOjRizszN M{PDZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
NOS-1 NGqwNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnWTpZKSzVyPUWyMlg2PTlizszN M1K2[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
NCI-H2342 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHNPGRPUUN3ME21N{4xPTB6IN88US=> NFzEdms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
KYSE-270 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rDdmlEPTB;NUOuOlM3PCEQvF2= M{myOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
LU-135 MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzP[FJVUUN3ME21OU4yQDV|IN88US=> Mn\2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
OE33 NYmyVVBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7zb3dIUUN3ME21OU45OThizszN NH7t[XA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
ML-2 MkHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;6fnpKSzVyPUW1Mlk1QDlizszN M1LielxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
KMOE-2 NX70ZmxbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYG5fmcxUUN3ME21Ok4zQDl|IN88US=> M4HVXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
Daoy NGLlWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;MTWM2OD13Nj6zNlA1KM7:TR?= MlzQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
KNS-62 NUnac5R6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Pl[GlEPTB;NUeuNFE1OiEQvF2= MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
NBsusSR NFTBWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlX6TWM2OD13Nz61O|A2KM7:TR?= NWLOV4hmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
UACC-257 NIq3eotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorxTWM2OD13OD62NlY1KM7:TR?= MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
LU-139 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlm5TWM2OD13OD64NlYh|ryP MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
CAL-85-1 Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDPfpJKSzVyPUW4Mlg3PDNizszN MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
NCI-H720 NWfvZnROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTV6Lki5OFIh|ryP M3T2ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
MLMA MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFj2ZlVKSzVyPUW5MlA6OSEQvF2= MlW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
A3-KAW MnjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPreJZKSzVyPUW5MlI5ODlizszN M1zMcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
Ramos-2G6-4C10 NFv4O2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTV7Lk[yPFch|ryP NFPtXpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
A388 NW[wOm5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLXTWM2OD14MD60OFkh|ryP NHHZbok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
LAMA-84 Mm[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfkSYZDUUN3ME22NE46QTB3IN88US=> NFPFV|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
GCT MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3wUXVsUUN3ME22NU4xPzh4IN88US=> NEj0cGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
K-562 NHH3blBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLqS2l{UUN3ME22NU42OzN|IN88US=> NWDrZoVSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
NCI-H1666 NH\wb2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFyzN5JKSzVyPU[xMlg4PSEQvF2= NWX0fJJJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
NCI-H1993 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTkZ5p4UUN3ME22N{41ODR|IN88US=> NF\VOVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
NCI-H358 NH3vTpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjHZlVKSzVyPU[1MlAyOjFizszN MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
NB6 MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHxVFJKSzVyPU[1Mlk5QCEQvF2= NEXuZok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
HCE-T NWP6c5NvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXs[XBKSzVyPU[3MlA4QThizszN MnzMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
DOK M1XYfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn32TWM2OD14Nz60PVQ5KM7:TR?= NWjQRlNSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
HT-1376 MliyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\ieVFKSzVyPU[5Mlg{OTRizszN NEn6PHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
NEC8 NI\SUlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYH5XYFVUUN3ME23NE4yOjR|IN88US=> M17Kd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
G-402 NIXJXFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTdyLkmzPVUh|ryP MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
GR-ST MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXuTWM2OD15MT6xO|Ih|ryP M1LrTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
QIMR-WIL MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPkO2RKSzVyPUexMlQ1OzRizszN NF7ZXZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
CHP-212 M4DGfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHvTWM2OD15MT65OlUh|ryP NGr1NXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
KU812 NYTL[JNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\CNGFWUUN3ME23Nk46PzB{IN88US=> NV;qTWxMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
Becker M2DTeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1q4b2lEPTB;N{OuNVQ5QSEQvF2= M1rwVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
ChaGo-K-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlftTWM2OD15ND63OFg3KM7:TR?= MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
A498 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jWW2lEPTB;N{SuPVMxQCEQvF2= NVSzbZRORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
NCI-H69 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVT0b4l3UUN3ME23OU44PjZ|IN88US=> M4jsd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
NCI-H209 M2HRPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{SwemlEPTB;N{iuOlE1PyEQvF2= MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
CAL-33 NF;vbolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Ho[WlEPTB;N{iuPVk{QSEQvF2= M4PCc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
COLO-680N NVLNfXlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrkdoFKSzVyPUe5MlExODdizszN MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
D-283MED NV;Sc3BWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTd7LkixNkDPxE1? NXTkV5FyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
ATN-1 M1PqPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7FTWM2OD16MT6xNVg4KM7:TR?= NH;sSW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
NCI-N87 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlWzTWM2OD16MT63Nlk3KM7:TR?= MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
MHH-NB-11 NFW1dFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLXTWM2OD16MT64PFQ6KM7:TR?= MkH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
HEL M4Lq[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moj2TWM2OD16Mj60NVM1KM7:TR?= MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
NB69 NGWxOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPl[ohKSzVyPUizMlAxOzNizszN M{jkNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
MPP-89 NYXWV251T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIewdGJKSzVyPUizMlI2PzVizszN MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
COLO-829 NXW0WnF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;pXmlEPTB;OEWuOFkyOiEQvF2= M{Pu[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
ONS-76 M4fH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTh3Lke5NFgh|ryP NWrCU2YxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
EW-3 NYWwOZVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTh4LkKwN|Ih|ryP M3HNdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
EW-11 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzRN3ZnUUN3ME24Ok41OzN4IN88US=> NHvlVGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
SW900 NHz3dHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTh5LkKwOVMh|ryP NXvabmZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
MOLT-13 NIW3bVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPsVmliUUN3ME24O{4zOjR|IN88US=> NGrHUG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
HuP-T4 Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HSTGlEPTB;OUGuNFQxPSEQvF2= Mm\GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
HCC1419 M2HpSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXQTWM2OD17MT62N|c1KM7:TR?= M1;HSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
CAL-72 MlSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVu4So5lUUN3ME25Nk4xOjF7IN88US=> NWTH[3VbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
Mo-T M{np[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTl{Lke2PVch|ryP M4LYZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
OC-314 NXXQWmwxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTl{Lki4NlEh|ryP NEfuU489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
BHT-101 NYKxbI42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:xepR[UUN3ME25N{4yKM7:TR?= NX7uRYR1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
EW-18 NVO5VYFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHi5ZZZKSzVyPUmzMlg1PjJizszN M3XQT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
TE-12 M1LiTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\2WndKSzVyPUm0MlMxPTVizszN NEXTcok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
MDA-MB-361 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;vTWM2OD17Nj6wOVE3KM7:TR?= MnLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
DF15 NHS2dYpHfW6ldHnvckBie3OjeR?= MoH6OEBpenN? M2LIO2lv\HWldHnvckBw\iCFUly0M2NTSk5idXLpdZVqfGmwIHzp[4F{\S2vZXTpZZRm\CCjaX;sc5Mh\GWpcnHkZZRqd25iaX6gbJVu[W5iRF[xOUBk\WyuczDlfJBz\XO|aX7nJJBNV0NvZWDMMZRi\2enZDDhbY9td3NiYX\0[ZIhPCCqcoOgZpkhdHWvaX7ld4NmdmOnIHLhd4VlKGKndHGt[4Ft[WO2b4Pp[IF{\SCnbor5cYUh\nKjZ33lcpRifGmxbjDjc41xdGWvZX70ZZRqd25iYYPzZZktKEWFNUCgQUAxNjB3MzFOwG0v MlflQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|NUi1NFcoRjJ6M{W4OVA4RC:jPh?=
DF15 NV7UcYVETnWwY4Tpc44h[XO|YYm= NXrWPWhlPCCqcoO= MWjJcoR2[3Srb36gc4Yh[2W{ZXLsc44udWWmaXH0[YQhcWujcn;zJIRm\3KjZHH0bY9vKGmwIHj1cYFvKESIMUWgZ4VtdHNiZYjwdoV{e2mwZzDlVGwufGGpZ3XkJIls[XKxczDh[pRmeiB2IHjyd{BjgSCudX3pco9u\XS{aXOgZY5idHm|aYOsJGVEPTBiPTCwMlA3PyEQvF2u MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR{NUeyNEc,Ojh2MkW3NlA9N2F-
DF15 MVzGeY5kfGmxbjDhd5NigQ>? MojwOEBpenN? NGrxcmVKdmS3Y4Tpc44hd2ZiY3Xy[YJtd25vbXXkbYF1\WRiYXnvcI9{KGSnZ4Lh[IF1cW:wIHnuJIh2dWGwIFTGNVUh[2WubIOg[ZhxemW|c3nu[{BmWExvdHHn[4VlKGGrb3zvd{Bi\nSncjC0JIhzeyCkeTDseY1qdm:vZYTybYMh[W6jbInzbZMtKEWFNUCgQUAxNjB6NzFOwG0v MkLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2MkW3NlAoRjJ6NEK1O|IxRC:jPh?=
T-cells MVHGeY5kfGmxbjDhd5NigQ>? MX6yJJRwKDNiZHH5dy=> M4DEc2lvcGmkaYTpc44hd2ZiSVytNkBxem:mdXP0bY9vKGmwIHj1cYFvKFRiY3XscJMhdWWjc4Xy[YQh[W[2ZYKgNkB1dyB|IHThfZMh[nliRVzJV2EtKEWFNUCgQUAxNjF3IN88UU4> M1vZTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MU[4NFE6Lz5{M{G2PFAyQTxxYU6=
NAMALWA M3rucWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M{m3c|czKGi{cx?= MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6DTVHMW2Eh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDbN2hefGi7bXnkbY5mKGmwY3;ydI9z[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoctKEmFNUCgQUAxNjN4IN88UU4> NEfSXmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G2PFAyQSd-MkOxOlgxOTl:L3G+
CD34+ progenitor cells NULuVJh5TnWwY4Tpc44h[XO|YYm= NUHNVJJTOTRiZHH5dy=> NY\YPJN7TGWlcnXhd4UhcW5iZYL5eIhzd2mmIHTp[oZmemWwdHnheIlwdiCxZjDDSFM1MyCycn;n[Y5qfG:{IHPlcIx{KG[{b32gcZlmdG:meYPwcIF{fGmlIIP5coRzd22nIHTlcEg2eSlicHH0bYVvfCCjc4Pld5Nm\CCjczDDSFM3KGW6cILld5Nqd25iYX\0[ZIhOTRiZHH5dy=> MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV5NkmyOEc,OTd3N{[5NlQ9N2F-
CD34+ progenitor cells MWfGeY5kfGmxbjDhd5NigQ>? MYixOEBl[Xm| MV3E[YNz\WG|ZTDpckBugWWub3nkJIRq\m[ncnXueIlifGmxbjDv[kBETDN2KzDwdo9o\W6rdH;yJINmdGy|IH\yc40hdXmnbH;kfZNxdGG|dHnjJJN6dmS{b33lJIRmdCh3cTmgdIF1cWWwdDDhd5Nme3OnZDDhd{BETDN|IHX4dJJme3Orb36gZYZ1\XJiMUSg[IF6ew>? MkjKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3N{[5NlQoRjF5NUe2PVI1RC:jPh?=
CD34+ progenitor cells MWfGeY5kfGmxbjDhd5NigQ>? NVHaT|dKOTRiZHH5dy=> M2HpWGRm[3KnYYPlJIlvKGW{eYTodo9q\CCmaX\m[ZJmdnSrYYTpc44hd2ZiQ1SzOEsheHKxZ3XubZRweiClZXzsd{Bnem:vIH35[Yxw\Hm|cHzhd5Rq[yC|eX7kdo9u\SCmZXyoOZEqKHCjdHnlcpQh[XO|ZYPz[YQh[XNiZ3z5Z49xcG:{aX6gRUBmgHC{ZYPzbY9vKGGodHXyJFE1KGSjeYO= NG\wWYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W3OlkzPCd-MUe1O|Y6OjR:L3G+
CD34+ progenitor cells MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NU\kUpRIOTRiZHH5dy=> NE\PdZNKdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDv[kBETDN2KzDwdo9o\W6rdH;yJINmdGy|IH\yc40hdXmnbH;kfZNxdGG|dHnjJJN6dmS{b33lJIRmdCh3cTmgdIF1cWWwdDDh[pRmeiBzNDDkZZl{ MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV5NkmyOEc,OTd3N{[5NlQ9N2F-
CD34+ progenitor cells M2PWfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn6zNVQh\GG7cx?= NF[xVY9Iem:5dHigbY5pcWKrdHnvckBw\iCFREO0L{Bxem:pZX7peI9zKGOnbHzzJIZzd21ibn;uMYRmdCh3cTmgcZlmdG:meYPwcIF{fGmlIIP5coRzd22nIIDheIlmdnRiYX\0[ZIhOTRiZHH5dy=> MmeyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3N{[5NlQoRjF5NUe2PVI1RC:jPh?=
DF15 NHjSV2dHfW6ldHnvckBie3OjeR?= NXzGeIN7OC5zIITvJFExKHWP NHnkc202KGi{cx?= NH3wTYxKdmS3Y4Tpc44hd2ZiY3Xy[YJtd25vbXXkbYF1\WRiYXnvcI9{KGSnZ4Lh[IF1cW:wIHnuJIh2dWGwIFTGNVUh[2WubIOgZZQhOC5zIITvJFExKHWPIHHmeIVzKDViaILzJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXN? NFPCZZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOVczOCd-Mki0NlU4OjB:L3G+
OPM2 MkfLSpVv[3Srb36gZZN{[Xl? M2q2UFAvOSC2bzCxNEB2VQ>? NHTZN4g2KGi{cx?= MUXJcoR2[3Srb36gc4Yh[2W{ZXLsc44udWWmaXH0[YQh[WmxbH;zJIRm\3KjZHH0bY9vKGmwIHj1cYFvKE:STUKgZ4VtdHNiYYSgNE4yKHSxIEGwJJVOKGGodHXyJFUhcHK|IHL5JIludXWwb3Lsc5Qh[W6jbInzbZM> NH7pcIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOVczOCd-Mki0NlU4OjB:L3G+
DF15 NH:4N2ZHfW6ldHnvckBie3OjeR?= MV6wMlEhfG9iMUCgeW0> NUnKeZVrPSCqcoO= NV:1SpFtUW6mdXP0bY9vKG:oIHPldoVjdG:wLX3l[IlifGWmIHnrZZJweyCmZXfyZYRifGmxbjDpckBpfW2jbjDESlE2KGOnbHzzJIF1KDBwMTD0c{AyOCC3TTDh[pRmeiB3IHjyd{BjgSCrbX31co9jdG:2IHHuZYx6e2m| M{S2NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK1O|IxLz5{OESyOVczODxxYU6=
OPM2 Moq4SpVv[3Srb36gZZN{[Xl? MoC3NE4yKHSxIEGwJJVO MlHhOUBpenN? MlfmTY5lfWO2aX;uJI9nKGOncnXicI9vNW2nZHnheIVlKGmtYYLvd{Bl\We{YXTheIlwdiCrbjDoeY1idiCRUF2yJINmdGy|IHH0JFAvOSC2bzCxNEB2VSCjZoTldkA2KGi{czDifUBqdW23bn;icI91KGGwYXz5d4l{ M3XQUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK1O|IxLz5{OESyOVczODxxYU6=
EC9706 NHPNRlBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MmX6NVUxKHWpL33M MWC0PEBpenN? NXfvOndHSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDFR|k4ODZiY3XscJMh[XRiMUWwJJVoN22OIHHmeIVzKDR6IHjyd{BjgSCFQ1utPEBie3OjeR?= MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd3N{C2Okc,Ojh5NUewOlY9N2F-
Assay
Methods Test Index PMID
Western blot phospho-IKKβ / IKKβ ; MDM2 / p-MDM2 / p-p53 / p53 22698399 22525275
Growth inhibition assay Cell viability 22698399
In vivo The induction of angiogenesis by bFGF is significantly inhibited by oral treatment of Lenalidomide in a dose-dependent manner. Lenalidomide significantly decreases the percentage of vascularized area from 5.16% (control group) to 2.58% (50 mg/kg). Lenalidomide significantly reduces the calculated total MVL from 21.07 (control) to 8.11 (50 mg/kg). Lenalidomide significantly inhibites HUVEC migration through the fibronectin-coated membranes towards 0.1 ng/mL of bFGF at 100 μM, 1 ng/mL of VEGF at concentrations of 10 μM and 100 μM. [5]

Protocol (from reference)

Animal Research:

[5]

  • Animal Models: Adult male Sprague-Dawley rats bearing HUVECs cells
  • Dosages: 50 mg/kg and 250 mg/kg
  • Administration: Administered via i.p.

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5% DMSO+40%PEG 300+5%Tween80+ddH2O
For best results, use promptly after mixing.

10mg/mL

Chemical Information

Molecular Weight 259.26
Formula

C13H13N3O3

CAS No. 191732-72-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05344833 Not yet recruiting Drug: Isatuximab|Drug: Lenalidomide Multiple Myeloma University of Illinois at Chicago May 31 2022 Phase 2
NCT05335018 Recruiting Drug: Glofitamab Poseltinib Lenalidomide Relapsed/Refractory Diffuse Large B Cell Lymphoma Seoul National University Hospital May 30 2022 Phase 2
NCT05091372 Not yet recruiting Drug: Belantamab mafodotin|Drug: Lenalidomide Myeloma Multiple M.D. Anderson Cancer Center April 30 2022 Phase 2
NCT04903197 Recruiting Drug: VAY736|Drug: lenalidomide Non-Hodgkin Lymphoma Diffuse Large B Cell Lymphoma Follicular Lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma Novartis Pharmaceuticals|Novartis January 24 2022 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
What is the formulation for mouse injection(i.p.)?

Answer:
This paper has the information you need: http://link.springer.com/article/10.1208/s12248-012-9401-2. Add lenalidomide to the appropriate volume of sterile phosphate-buffered saline (PBS) containing 1% hydrochloric acid (HCl). the pH of this preparation was adjusted to 7.0–7.6 using sodium hydroxide and sterile filtered using a 0.22 μm Steriflip filter.

Question 2:
what is the procedure to resuspend this compound?

Answer:
You can resuspend this compund by DMSO, the solubility is about 52 mg/mL (200.57 mM). For in vivo study, you can prepare the working solution with the vehicle of: 30% PEG400/0.5% Tween80/5% propylene glycol for oral administration.

Tags: buy Lenalidomide (CC-5013) | Lenalidomide (CC-5013) supplier | purchase Lenalidomide (CC-5013) | Lenalidomide (CC-5013) cost | Lenalidomide (CC-5013) manufacturer | order Lenalidomide (CC-5013) | Lenalidomide (CC-5013) distributor